Adjuvant Lactiplantibacillus plantarum Lp05 modulates gut microbiota and alleviates symptoms during Helicobacter pylori eradication.

H. pylori eradication rates did not differ significantly between the Lp05 and placebo groups.

• Eradication rate in the Lp05 group was 97.1% compared to 94.1% in the placebo group.
• The difference was not statistically significant (P > 0.05).
• Both groups received bismuth quadruple therapy as the primary eradication regimen.
• This indicates that Lp05 supplementation did not interfere with the primary therapeutic goal of H. pylori eradication.

Lp05 supplementation significantly reduced key gastrointestinal symptoms, including abdominal pain and acid reflux, during H. pylori eradication therapy.

• Statistically significant reductions in abdominal pain and acid reflux were observed in the Lp05 group (P < 0.05).
• The trial was randomized, double-blind, and placebo-controlled with 72 H. pylori-positive patients.
• Patients received Lp05 or placebo for 2 weeks alongside bismuth quadruple therapy, followed by a 4-week extension of probiotic or placebo alone.
• The reduction in gastrointestinal symptoms suggests improved tolerability of standard eradication therapy with Lp05 adjunction.

Lp05 supplementation attenuated antibiotic-induced gut microbiota dysbiosis by selectively enriching beneficial genera and suppressing opportunistic pathogens.

• Gut microbiota composition was assessed via 16S rRNA gene sequencing.
• Lp05 supplementation led to selective enrichment of beneficial genera including Akkermansia and Bifidobacterium.
• Opportunistic pathogens were suppressed in the Lp05 group compared to placebo.
• These changes suggest Lp05 contributes to maintenance of gut microbiota balance during antibiotic-based H. pylori treatment.

The study design was a randomized, double-blind, placebo-controlled trial registered with the Chinese Clinical Trial Registry.

• 72 H. pylori-positive patients were enrolled and randomized to receive either Lp05 or placebo.
• The intervention period consisted of 2 weeks of bismuth quadruple therapy combined with Lp05 or placebo, followed by a 4-week extension of probiotic or placebo alone.
• Outcomes evaluated included gastrointestinal symptoms, safety outcomes, and gut microbiota composition.
• The trial is registered as ChiCTR2400079562.

Lp05 adjunct therapy was found to be safe and did not interfere with primary eradication efficacy.

• Safety outcomes were explicitly evaluated as part of the trial endpoints.
• The eradication rates remained high in both groups (97.1% Lp05 vs. 94.1% placebo), with no significant difference.
• The authors conclude that Lp05 'fulfills the paramount requirements of safety and noninterference with primary eradication efficacy.'
• No adverse safety signals related to Lp05 supplementation were reported as a concern in the abstract.